Phase I Study of MT1011 Injection in Healthy Subjects

Phase 1 Recruiting 40 enrolled Shaanxi Micot Pharmaceutical Technology Co., Ltd.

RandomizedSequentialQuadruple-blindTreatment

Summary

This is a single-center, randomized,double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) of MT1011 injection in healthy adult subjects. Includes 5 dose cohorts, with 40 subjects planned for enrollment.

Timeline

Start: 2025-06-25
Primary completion: 2026-04
Completion: 2026-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MT1011	Small molecule	—	—

Indications

No indication recorded.